Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Myocarditis I: Introduction

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Climbing to the Summit of Guideline Directed Therapy of Heart Failure:A Slippery Slope.

The American journal of cardiology·2025

Same author

Benchmarking Large Language Models for Extraction of International Classification of Diseases Codes from Clinical Documentation.

medRxiv : the preprint server for health sciences·2024

Same author

Extracting International Classification of Diseases Codes from Clinical Documentation Using Large Language Models.

Applied clinical informatics·2024

Same author

Assessment and Follow-Up of the Aortic Root by 2-Dimensional Echocardiography.

The American journal of cardiology·2024

Same author

Elevated Lp(a): Guidance for Identifying and Managing Patients.

Southern medical journal·2024

Same author

What AHRQ Learned While Working to Transform Primary Care.

Annals of family medicine·2024

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Anthracycline-induced cardiomyopathy.

Ashley Simmons¹, James L Vacek, David Meyers

¹Division of Cardiovascular Diseases, University of Kansas School of Medicine, Kansas City, KS 66160, USA.

Postgraduate Medicine

|November 21, 2008

Summary

Anthracycline chemotherapy can cause cardiomyopathy, a heart muscle disease. Early diagnosis and treatment with medications like beta-blockers and ACE inhibitors are crucial for managing this condition.

Area of Science:

Cardiology
Oncology
Pharmacology

Background:

Anthracyclines are vital chemotherapy drugs.
These drugs can lead to three distinct types of cardiomyopathy.
Cardiomyopathy may manifest acutely or chronically after treatment.

Purpose of the Study:

To review current research on anthracycline-induced myocardial damage.
To discuss noninvasive diagnostic imaging for this condition.
To explore future research directions, including genetic screening and prophylactic treatments.

Main Methods:

Literature review of recent research.
Analysis of diagnostic imaging techniques.
Discussion of potential therapeutic strategies.

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

Related Experiment Videos

Last Updated: Jun 27, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

Main Results:

Anthracycline-induced cardiomyopathy presents in acute and chronic forms.
Treatment strategies mirror those for ischemic cardiomyopathies.
Beta-blockade and ACE inhibition are standard treatments.

Conclusions:

Understanding mechanisms of myocardial damage is key.
Noninvasive imaging aids in early diagnosis.
Future research should focus on risk stratification and prevention, potentially using carvedilol and ACE inhibitors.